Entities / Company
Autolus Therapeutics.
company in London, United Kingdom
- Reports this week
- 0
- Active events
- 0
- Connections
- 45
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
-
Autolus Therapeutics is well capitalized and ready to drive the launch and commercialization of its product, obe-cel.Well supported5 reports
-
Autolus Therapeutics is listing its ADR shares on the Nasdaq exchange, and Jefferies Financial Group has issued research reports on the company.Some support2 reports
Gone quiet
No new reports in 90+ days-
Autolus Therapeutics received conditional marketing authorization in Europe on August 13, 2025, alongside a related CMS decision on split reimbursement.Some support2 reports
-
Amanda Cray serves as Executive Director at Autolus Therapeutics.Some support3 reports
-
AstraZeneca and Autolus Therapeutics are driving investment and innovation in cancer treatment within the US market.Some support1 report1 development inside
-
Autolus Therapeutics reported positive clinical trial results for its next-generation T cell therapies, including AUCATZYL®.Some support1 report
-
Autolus Therapeutics announced its financial results from London and Gaithersburg on July 24, 2025.Some support2 reports
-
AGC Biologics supplies vital lentiviral vector to Autolus Therapeutics.Some support1 report
-
Needham reiterated a Buy rating on Autolus Therapeutics while acknowledging the potential of AI stocks.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Autolus Therapeutics this week
News at the entities that move Autolus Therapeutics most-
Nice StructuralViolence and riots in Nice and Lyon are negatively impacting the local tourism sector and hotel reservations.Moves Autolus Therapeutics
-
Jefferies Financial Group Mentioned togetherJefferies Financial Group lowered its shares rating for Gibson Energy on July 31, 2026.Moves Autolus Therapeutics
-
MarketBeat Mentioned togetherDavidson began coverage, MarketBeat reported consensus ratings, and Keefe, Bruyette & Woods boosted the price target for Chemung Financial Corp.Moves Autolus Therapeutics
-
Nasdaq StructuralApple Inc. debuted its new foldable smartphone on September 10, 2026.Moves Autolus Therapeutics
Connections
The 6 strongest of 45, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Nasdaq Structural
Autolus Therapeutics is listed on the Nasdaq exchange via ADR shares, establishing a market dependency.
-
Nice Structural
Autolus Therapeutics depends on NICE's formal appraisal and reimbursement decisions to bring its therapy to UK patients.
-
Jefferies Financial Group Mentioned together
Jefferies Financial Group provides financial research and rating coverage for Autolus Therapeutics.
-
MarketBeat Mentioned together
MarketBeat aggregates financial data, including coverage of Autolus Therapeutics, as part of its market overview.
-
CAR Mentioned together
Both entities are mentioned in the context of AUCATZYL's revenue growth and cancer treatment development.
-
The Review Panel Mentioned together
The evidence provided does not contain direct coupling or interaction between The Review Panel and Autolus Therapeutics.
History
Events by the month they beganAugust 2026
1 eventJune 2026
8 events- Autolus Therapeutics is well capitalized and ready to drive the launch and commercialization of its product, obe-cel.
- Autolus Therapeutics received conditional marketing authorization in Europe on August 13, 2025, alongside a related CMS decision on split reimbursement.
- Amanda Cray serves as Executive Director at Autolus Therapeutics.
- AstraZeneca and Autolus Therapeutics are driving investment and innovation in cancer treatment within the US market.
- Autolus Therapeutics reported positive clinical trial results for its next-generation T cell therapies, including AUCATZYL®.
- Autolus Therapeutics announced its financial results from London and Gaithersburg on July 24, 2025.
- AGC Biologics supplies vital lentiviral vector to Autolus Therapeutics.
- Needham reiterated a Buy rating on Autolus Therapeutics while acknowledging the potential of AI stocks.